Combining drugs and extending treatment - a PFS end point is not sufficient

Nat Rev Clin Oncol. 2017 Sep;14(9):521-522. doi: 10.1038/nrclinonc.2017.72. Epub 2017 May 23.

Authors

Bishal Gyawali¹, Vinay Prasad^{2

3

4}

Affiliations

¹ Institute of Cancer Policy, King's College London, SE1 9RT, UK.
² Division of Hematology Oncology in the Knight Cancer Institute, Oregon Health and Sciences University (OHSU).
³ Department of Public Health and Preventive Medicine, OSHU.
⁴ Center for Health Care Ethics, OSHU, 3181 South West Sam Jackson Park Road, Portland, Oregon 97239-3098, USA.

PMID: 28534528
DOI: 10.1038/nrclinonc.2017.72

No abstract available

Publication types

Review

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / administration & dosage
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Disease-Free Survival
Drug Administration Schedule
Humans
Neoplasms / drug therapy*
Treatment Outcome